Jiangxi Fushine Pharmaceutical Co Ltd (300497) - Total Assets
Based on the latest financial reports, Jiangxi Fushine Pharmaceutical Co Ltd (300497) holds total assets worth CN¥4.44 Billion CNY (≈ $649.40 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Jiangxi Fushine Pharmaceutical Co Ltd's book value for net asset value and shareholders' equity analysis.
Jiangxi Fushine Pharmaceutical Co Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Jiangxi Fushine Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.
Jiangxi Fushine Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Jiangxi Fushine Pharmaceutical Co Ltd's total assets of CN¥4.44 Billion consist of 37.1% current assets and 63.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 15.3% |
| Accounts Receivable | CN¥526.19 Million | 11.6% |
| Inventory | CN¥421.05 Million | 9.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥235.00 Million | 5.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Jiangxi Fushine Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 300497 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangxi Fushine Pharmaceutical Co Ltd's current assets represent 37.1% of total assets in 2024, a decrease from 52.2% in 2011.
- Cash Position: Cash and equivalents constituted 15.3% of total assets in 2024, down from 15.7% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 17.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 11.6% of total assets.
Jiangxi Fushine Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Jiangxi Fushine Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Jiangxi Fushine Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.14 | 1.16 | 2.67 |
| Quick Ratio | 0.84 | 0.86 | 2.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥192.67 Million | CN¥231.21 Million | CN¥1.48 Billion |
Jiangxi Fushine Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jiangxi Fushine Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.11 |
| Latest Market Cap to Assets Ratio | 0.34 |
| Asset Growth Rate (YoY) | -5.9% |
| Total Assets | CN¥4.54 Billion |
| Market Capitalization | $1.52 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Jiangxi Fushine Pharmaceutical Co Ltd's assets below their book value (0.34x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Jiangxi Fushine Pharmaceutical Co Ltd's assets decreased by 5.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Jiangxi Fushine Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual total assets of Jiangxi Fushine Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.54 Billion ≈ $663.89 Million |
-5.86% |
| 2023-12-31 | CN¥4.82 Billion ≈ $705.18 Million |
-4.76% |
| 2022-12-31 | CN¥5.06 Billion ≈ $740.41 Million |
+8.15% |
| 2021-12-31 | CN¥4.68 Billion ≈ $684.61 Million |
+15.64% |
| 2020-12-31 | CN¥4.05 Billion ≈ $592.01 Million |
+55.85% |
| 2019-12-31 | CN¥2.60 Billion ≈ $379.85 Million |
+18.18% |
| 2018-12-31 | CN¥2.20 Billion ≈ $321.41 Million |
+22.75% |
| 2017-12-31 | CN¥1.79 Billion ≈ $261.85 Million |
+27.96% |
| 2016-12-31 | CN¥1.40 Billion ≈ $204.63 Million |
+38.50% |
| 2015-12-31 | CN¥1.01 Billion ≈ $147.74 Million |
+59.67% |
| 2014-12-31 | CN¥632.35 Million ≈ $92.53 Million |
+16.82% |
| 2013-12-31 | CN¥541.31 Million ≈ $79.21 Million |
+13.65% |
| 2012-12-31 | CN¥476.31 Million ≈ $69.70 Million |
+35.10% |
| 2011-12-31 | CN¥352.57 Million ≈ $51.59 Million |
-- |
About Jiangxi Fushine Pharmaceutical Co Ltd
Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers ß-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride… Read more